Cloxacillin Sodium Capsules
» Cloxacillin Sodium Capsules contain the equivalent of not less than 90.0 percent and not more than 120.0 percent of the labeled amount of cloxacillin (C19H18ClN3O5S).
Packaging and storage— Preserve in tight containers.
USP Reference standards 11
USP Cloxacillin Sodium RS Click to View Structure
Dissolution 711
Medium: 0.05 M pH 6.8 potassium phosphate buffer; 900 mL.
Apparatus 1: 100 rpm.
Time: 30 minutes.
Procedure— Determine the amount of cloxacillin (C19H18ClN3O5S) dissolved by employing the method set forth in the Assay, in comparison with a Standard solution having a known concentration of USP Cloxacillin Sodium RS in the Dissolution Medium.
Tolerances— Not less than 80% (Q) of the labeled amount of cloxacillin (C19H18ClN3O5S) is dissolved in 30 minutes.
Uniformity of dosage units 905: meet the requirements.
Water, Method I 921: not more than 5.0%.
Buffer, Mobile phase, Standard preparation, and Chromatographic system— Proceed as directed in the Assay under Cloxacillin Sodium.
Assay preparation— Weigh and finely powder the contents of not fewer than 10 Capsules. Transfer an accurately weighed quantity of the powder, equivalent to about 100 mg of cloxacillin, to a 200-mL volumetric flask, dilute with Buffer to volume, mix, and stir for 10 minutes. Filter about 25 mL of this mixture, discarding the first 5 mL of the filtrate. Use the clear filtrate as the Assay preparation.
Procedure— Proceed as directed for Procedure in the Assay under Cloxacillin Sodium. Calculate the quantity, in mg, of cloxacillin (C19H18ClN3O5S) in the portion of Capsule contents taken by the formula:
0.2CE(rU / rS)
in which the terms are as defined therein.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Ahalya Wise, M.S.
Senior Scientific Liaison
(SM12010) Monographs - Small Molecules 1
Reference Standards RS Technical Services
711 Margareth R.C. Marques, Ph.D.
Senior Scientific Liaison
(GCDF2010) General Chapters - Dosage Forms
USP35–NF30 Page 2747
Pharmacopeial Forum: Volume No. 28(4) Page 1092